Analysts Maintain Optimism on Fennec Pharmaceuticals Despite Share Price Dip Shares of Fennec Pharmaceuticals have recently declined, trading around $6.09, but analyst sentiment remains supportive. Both HC Wainwright and Wedbush reaffirmed their 'buy' and 'outperform' ratings with a $13 price target. Insider selling has occurred, but nearly 11% of shares remain held by company insiders, reflecting ongoing confidence.12